← Back
Data updated: Mar 29, 2026
PERRIGO
GastroenterologyImmunology
Generics
PERRIGO is a generic drug manufacturer focused on Gastroenterology, Immunology.
1983
Since
30
Drugs
-
Trials
127
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-15
Labeling
LOPERAMIDE HYDROCHLORIDE 2025-12-29
ACETAMINOPHEN 2025-12-05
LOPERAMIDE HYDROCHLORIDE 2025-11-17
DIPHENHYDRAMINE HYDROCHLORIDE 2025-11-14
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Gastroenterology 50%
1 drugs
Immunology 50%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Active (13)
Discontinued (17)
ACETAMINOPHEN DIPHENHYDRAMINE HYDROCHLORIDE MICONAZOLE NITRATE QUINIDINE SULFATE ISONIAZID KETOPROFEN CIMETIDINE DOXYLAMINE SUCCINATE DESLORATADINE IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE MEPROBAMATE TAB-PROFEN CAP-PROFEN SODIUM PENTOBARBITAL SECOBARBITAL SODIUM ANTITUSSIVE
Company Info
- First Approval
- 1983-01-25
- Latest
- 2024-04-04
- Applications
- 40